Pharming Group N.V. today announced The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical trial (NCT02247739) evaluating the efficacy and safety of RUCONEST® (C1 esterase inhibitor [recombinant]) for the prevention of hereditary angioedema (HAE) attacks.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. today announced that the supervisory board and the management board have jointly decided to withdraw the agenda items related to the Amendment of Pharming’s Articles of Association from the agenda of the AGM scheduled for Wednesday, 24 May 2017 at 14:00 hours.

Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2017.

On May the 16th Hereditary Angioedema (HAE) patient organizationsfrom around the world, led by HAEi ( The international HAE patient organisation) come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.

Pharming Group N.V. announces that it has completed a new US$100 million finance agreement with Orbimed Advisors.

Pharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.

Pharming Group N.V. today announces that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).

Pharming Group N.V. today announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs.

Prospectus 2016 is available for download.